JP2018521983A - がんを治療するための組成物および方法 - Google Patents

がんを治療するための組成物および方法 Download PDF

Info

Publication number
JP2018521983A
JP2018521983A JP2017563950A JP2017563950A JP2018521983A JP 2018521983 A JP2018521983 A JP 2018521983A JP 2017563950 A JP2017563950 A JP 2017563950A JP 2017563950 A JP2017563950 A JP 2017563950A JP 2018521983 A JP2018521983 A JP 2018521983A
Authority
JP
Japan
Prior art keywords
peptide
seq
antagonist
agonist
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521983A5 (OSRAM
Inventor
アムノン ペレド
アムノン ペレド
ヤロン ぺレグ
ヤロン ぺレグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BiolineRx Ltd
Original Assignee
BiolineRx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BiolineRx Ltd filed Critical BiolineRx Ltd
Publication of JP2018521983A publication Critical patent/JP2018521983A/ja
Publication of JP2018521983A5 publication Critical patent/JP2018521983A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2017563950A 2015-07-16 2016-07-14 がんを治療するための組成物および方法 Pending JP2018521983A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562193201P 2015-07-16 2015-07-16
US62/193,201 2015-07-16
US201562259182P 2015-11-24 2015-11-24
US62/259,182 2015-11-24
US201662291006P 2016-02-04 2016-02-04
US201662291039P 2016-02-04 2016-02-04
US62/291,006 2016-02-04
US62/291,039 2016-02-04
PCT/IL2016/050764 WO2017009842A2 (en) 2015-07-16 2016-07-14 Compositions and methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020216934A Division JP2021050239A (ja) 2015-07-16 2020-12-25 がん治療用に特定された製品

Publications (2)

Publication Number Publication Date
JP2018521983A true JP2018521983A (ja) 2018-08-09
JP2018521983A5 JP2018521983A5 (OSRAM) 2019-07-04

Family

ID=56555511

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017563950A Pending JP2018521983A (ja) 2015-07-16 2016-07-14 がんを治療するための組成物および方法
JP2020216934A Pending JP2021050239A (ja) 2015-07-16 2020-12-25 がん治療用に特定された製品
JP2022098896A Pending JP2022113913A (ja) 2015-07-16 2022-06-20 抗ｐｄ１抗体と組み合わせて使用されるペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020216934A Pending JP2021050239A (ja) 2015-07-16 2020-12-25 がん治療用に特定された製品
JP2022098896A Pending JP2022113913A (ja) 2015-07-16 2022-06-20 抗ｐｄ１抗体と組み合わせて使用されるペプチドおよびその使用

Country Status (12)

Country Link
US (22) US10786547B2 (OSRAM)
EP (3) EP3744340A3 (OSRAM)
JP (3) JP2018521983A (OSRAM)
KR (2) KR20180063881A (OSRAM)
CN (4) CN107921087A (OSRAM)
AU (3) AU2016291817A1 (OSRAM)
BR (1) BR112018000903A2 (OSRAM)
CA (1) CA2986705A1 (OSRAM)
HK (1) HK1248602A1 (OSRAM)
IL (3) IL274572B2 (OSRAM)
MX (2) MX2017016844A (OSRAM)
WO (2) WO2017009842A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240116531A (ko) 2015-02-09 2024-07-29 슬링샷 바이오사이언시즈 인코포레이티드 튜닝가능한 광 특성을 갖는 하이드로겔 입자 및 이를 사용하기 위한 방법
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
MX2019011324A (es) 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
AU2018256453B2 (en) * 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
US11471506B2 (en) * 2018-04-23 2022-10-18 Emory University VIP antagonists and uses in treating cancer
CN112996502B (zh) * 2018-05-16 2023-10-31 普罗维克图斯药品技术公司 卤代呫吨针对难治性小儿实体瘤的体外和异种移植抗肿瘤活性
CN108997478B (zh) * 2018-08-06 2021-09-21 中国药科大学 一种具有免疫检查点拮抗活性的多肽及其应用
EP3836974A4 (en) * 2018-08-18 2022-06-15 President and Fellows of Harvard College IN SITU GENE EDIT
WO2020065647A1 (en) 2018-09-25 2020-04-02 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
US12291570B2 (en) * 2018-10-17 2025-05-06 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148744A1 (en) 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
US20220072087A1 (en) 2019-01-17 2022-03-10 Biolinerx Ltd. Specific combination therapy for treatment of pancreatic cancer
MX2021011654A (es) * 2019-04-03 2022-02-21 Targimmune Therapeutics Ag Inmunoterapia para el tratamiento del cancer.
CN113811541A (zh) * 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
WO2021009761A1 (en) * 2019-07-18 2021-01-21 Biolinerx Ltd. Combination therapy for the treatment of cancer
CA3235582A1 (en) 2021-10-29 2023-05-04 Anh Tuan Nguyen Hydrogel particles as feeder cells and as synthetic antigen presenting cells
EP4519690A1 (en) 2022-05-05 2025-03-12 Slingshot Biosciences, Inc. Engineered particles as red blood cell mimics and compositions containing same for hematology
WO2023234954A1 (en) * 2022-06-03 2023-12-07 Immunocore Limited Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors
CN120712108A (zh) 2022-10-26 2025-09-26 弹弓生物科学公司 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法
WO2025049609A1 (en) 2023-08-29 2025-03-06 Slingshot Biosciences, Inc. Cd34 stem cell mimics
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107333A (ja) * 2002-08-27 2004-04-08 Takeda Chem Ind Ltd Ｃｘｃｒ４拮抗薬およびその用途
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS552602A (en) 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd 1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
EP0215126B1 (en) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP1186663A1 (en) 1985-08-23 2002-03-13 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
ATE74272T1 (de) 1986-01-22 1992-04-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE65403T1 (de) 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (de) 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5202117A (en) 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2143335C (en) 1992-08-31 2000-03-14 Thierry Boon-Falleur Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09500788A (ja) 1993-07-26 1997-01-28 ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
RU2136696C1 (ru) 1993-10-14 1999-09-10 Сейкагаку Корпорейшн Новый полипептид и фармацевтическая композиция против вич-инфекции
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
DE69524264T2 (de) 1994-03-01 2002-07-18 Ludwig Institute For Cancer Research, New York Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
ES2281899T3 (es) 1994-05-06 2007-10-01 Institut Gustave Roussy Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo.
NZ305083A (en) 1995-03-01 1999-06-29 Immunex Corp Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
JP2911056B2 (ja) 1995-04-08 1999-06-23 株式会社エルジ化学 ヒト４−１ｂｂに特異的なモノクローナル抗体およびこれを産生する細胞株
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CA2268340A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
IL130123A (en) 1996-11-28 2007-07-24 Roussy Inst Gustave LAG-3 protein mutants, their expression, use and method of production
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
CA2290443A1 (en) 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Peptide parathyroid hormone analogs
JP4562815B2 (ja) 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
EP0998217B1 (en) 1997-05-23 2009-01-07 ProRhythm, Inc. Disposable high intensity focused ultrasound applicator
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2000006086A2 (en) 1998-07-31 2000-02-10 The Trustees Of Columbia University In The City Of New York Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6294459B1 (en) 1998-09-03 2001-09-25 Micron Technology, Inc. Anti-reflective coatings and methods for forming and using same
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
EP1124614A1 (de) 1998-10-27 2001-08-22 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
CN1297281C (zh) 1999-03-29 2007-01-31 希拉生物化学股份有限公司 治疗白血病的方法
EP1185687A1 (en) 1999-05-03 2002-03-13 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
JP2003516324A (ja) 1999-11-24 2003-05-13 シェーリング コーポレイション 転移を阻害する方法
GB9927757D0 (en) 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
BR0108001A (pt) 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
WO2001064716A1 (fr) 2000-03-03 2001-09-07 Nobutaka Fujii Composes antiviraux
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP2004501624A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
AU2001284419A1 (en) 2000-09-05 2002-03-22 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
AU2001291087A1 (en) 2000-09-20 2002-04-02 Amgen Inc. B7-like molecules and uses thereof
US6469543B1 (en) 2000-11-09 2002-10-22 Honeywell International Inc. High speed output buffers using voltage followers
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (ja) 2001-02-16 2003-02-10 サンケン電気株式会社 スイッチング電源装置
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ATE519779T1 (de) 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US6887673B2 (en) 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
AU2003288994A1 (en) 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
AU2003294930B2 (en) 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1608318A4 (en) 2003-03-27 2009-07-29 Univ Emory CXCR4 ANTAGONISTS AND METHOD OF USE
CA2520586C (en) 2003-03-27 2011-06-14 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
BRPI0414924A (pt) 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005037306A1 (en) 2003-10-17 2005-04-28 Novo Nordisk A/S Combination therapy
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
PT1726310E (pt) 2004-03-19 2012-04-27 Morinaga Milk Industry Co Ltd Fármaco para a terapêutica do cancro
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
US20060287229A1 (en) 2004-07-01 2006-12-21 Dani Eshel Novel CD40 variants
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
EP1773846A4 (en) 2004-07-13 2008-10-08 Univ British Columbia INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
BRPI0514343A (pt) 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
WO2006050270A2 (en) 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
EP1850872A4 (en) 2005-02-15 2008-10-15 Gtc Biotherapeutics Inc METHOD FOR USE OF ANTI-CD-137 ANTIBODY AS RADIOIMMUN THERAPY OR RADIO IMMUNE DETECTION MEANS
EP1851244A4 (en) 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
EP2650020B1 (en) 2005-05-06 2016-08-24 Providence Health & Services - Oregon Trimeric OX40-immunoglobulin fusion protein and methods of use
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US9034814B2 (en) 2005-05-25 2015-05-19 Hadasit Medical Research Services And Development Ltd. CXCR4 antagonists for wound healing and re-epithelialization
US8389708B2 (en) 2005-06-15 2013-03-05 Weiping Min Method of cancer treatment using siRNA silencing
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007035518A2 (en) 2005-09-15 2007-03-29 Duke University Aptamers as agonists
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
CN101573441A (zh) 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 非常小的胚胎样（vsel）干细胞及分离和利用其的方法
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
JP5093097B2 (ja) 2006-03-03 2012-12-05 小野薬品工業株式会社 細胞表面機能分子の細胞外領域多量体
EP2489728A1 (en) 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
MX2009001272A (es) 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
US7968098B2 (en) 2006-08-04 2011-06-28 Kurume University HLA-A24-binding KIF-derived peptide
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
GB0624308D0 (en) 2006-12-05 2007-01-17 Molmed Spa Combination product
CA2673484A1 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
CA2675291C (en) 2007-01-11 2017-05-23 Novo Nordisk A/S Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
WO2008115804A1 (en) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
GB0722274D0 (en) 2007-11-13 2007-12-27 Ludwig Inst Cancer Res New therapeutic method
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
EP2067402A1 (en) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transponson-mediated mutagenesis in spermatogonial stem cells
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009126804A2 (en) 2008-04-11 2009-10-15 The Regents Of The University Of Colorado, A Body Corporate Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
EP2291187B1 (en) 2008-04-24 2018-08-15 Newlink Genetics Corporation Ido inhibitors
US9931386B2 (en) 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010012506A1 (en) 2008-07-31 2010-02-04 Bionorica Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
AU2009286247A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a CD40 agonist to a tumor draining lymph node of a subject
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
CN102421913A (zh) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
MX2011009989A (es) 2009-03-23 2011-10-14 Ambit Biosciences Corp Metodos de tratamiento utilizando terapia de combinacion.
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2243833A1 (en) 2009-04-22 2010-10-27 Erasmus University Medical Center Rotterdam Method for the treatment of acute myeloid leukemia
WO2010146578A2 (en) 2009-06-14 2010-12-23 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
BRPI1009716A2 (pt) 2009-06-15 2016-10-11 Biokine Therapeutics Ltd ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
CA2775761C (en) 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011069121A1 (en) 2009-12-04 2011-06-09 Neostem, Inc. Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
EP2520589B1 (en) 2009-12-29 2018-11-07 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
EP2533779A4 (en) 2010-02-09 2013-08-21 Georgia Health Sciences University Res Inst Inc ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
HUE040213T2 (hu) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
US20120082687A1 (en) 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
JP2014506576A (ja) 2011-02-10 2014-03-17 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド ４−１ｂｂｌを含むアジュバント組成物
CN106749662B (zh) 2011-03-31 2021-06-18 国家医疗保健研究所 抗icos的抗体及其用途
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
RS58102B1 (sr) 2011-11-09 2019-02-28 Bristol Myers Squibb Co Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom
CN103170757A (zh) * 2011-12-23 2013-06-26 富泰华工业（深圳）有限公司 锡膏及其制备方法
EP2819703A4 (en) 2012-02-29 2015-11-18 Benitec Biopharma Ltd PAIN TREATMENT
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US20140147411A1 (en) * 2012-11-14 2014-05-29 U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS Methods of treating cancer and testing mutation zygosity related thereto
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
AU2013352156B2 (en) 2012-11-27 2018-12-06 Children's Medical Center Corporation Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
BR112015013183A2 (pt) 2012-12-05 2017-09-26 Thevax Genetics Vaccine Co Ltd proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014205036A1 (en) 2013-01-08 2015-07-30 Benitec Biopharma Limited Age-related macular degeneration treatment
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
ES2644022T3 (es) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
CN105324362B (zh) 2013-03-15 2017-05-24 百时美施贵宝公司 Ido抑制剂
US9675571B2 (en) 2013-03-15 2017-06-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (IDO)
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6294459B2 (ja) 2013-03-24 2018-03-14 バイオカイン・セラピューティクス・リミテッドＢｉｏｋｉｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 骨髄性白血病の処置方法
CN105682683A (zh) * 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014343214B2 (en) 2013-10-31 2020-04-09 Biolinerx Ltd. Methods of treating acute myeloid leukemia with a FLT3 mutation
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
US20180161366A1 (en) 2015-05-20 2018-06-14 Biokine Therapeutics Ltd. Methods of obtaining mononuclear blood cells and uses thereof
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
US12291570B2 (en) 2018-10-17 2025-05-06 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004107333A (ja) * 2002-08-27 2004-04-08 Takeda Chem Ind Ltd Ｃｘｃｒ４拮抗薬およびその用途
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
US20200276267A1 (en) 2020-09-03
US20200297805A1 (en) 2020-09-24
WO2017009842A3 (en) 2017-02-23
US20200297804A1 (en) 2020-09-24
AU2022231657B2 (en) 2025-04-10
US11554159B2 (en) 2023-01-17
US20200297807A1 (en) 2020-09-24
US11638742B2 (en) 2023-05-02
US10786547B2 (en) 2020-09-29
US20200297809A1 (en) 2020-09-24
EP3943098A2 (en) 2022-01-26
IL274572A (en) 2020-06-30
US20200390855A1 (en) 2020-12-17
CN115887671A (zh) 2023-04-04
IL274572B1 (en) 2023-09-01
US11590200B2 (en) 2023-02-28
EP3943098A3 (en) 2022-05-11
CN107921087A (zh) 2018-04-17
US11559562B2 (en) 2023-01-24
HK1248602A1 (zh) 2018-10-19
US11642393B2 (en) 2023-05-09
KR20210089270A (ko) 2021-07-15
US11596666B2 (en) 2023-03-07
EP3744340A2 (en) 2020-12-02
US20180140670A1 (en) 2018-05-24
CN111375066A (zh) 2020-07-07
EP3744340A3 (en) 2021-03-03
IL255929A (en) 2018-01-31
AU2020203840B2 (en) 2022-06-23
US20200268846A1 (en) 2020-08-27
US20200297806A1 (en) 2020-09-24
AU2016291817A1 (en) 2018-02-22
BR112018000903A2 (pt) 2018-09-11
US11638743B2 (en) 2023-05-02
US20180140660A1 (en) 2018-05-24
IL274572B2 (en) 2024-01-01
US20200297810A1 (en) 2020-09-24
US20200268840A1 (en) 2020-08-27
JP2021050239A (ja) 2021-04-01
US11607444B2 (en) 2023-03-21
US20200268841A1 (en) 2020-08-27
IL304820A (en) 2023-09-01
US11612638B2 (en) 2023-03-28
CN116196426A (zh) 2023-06-02
US20200297802A1 (en) 2020-09-24
CN111375066B (zh) 2023-04-25
US20200297811A1 (en) 2020-09-24
US20200297808A1 (en) 2020-09-24
US20200268845A1 (en) 2020-08-27
MX2017016844A (es) 2018-08-15
US20200268842A1 (en) 2020-08-27
WO2017009843A3 (en) 2017-06-08
US20200297812A1 (en) 2020-09-24
EP3322431A2 (en) 2018-05-23
US11534478B2 (en) 2022-12-27
US20200297803A1 (en) 2020-09-24
US20200268844A1 (en) 2020-08-27
AU2020203840A1 (en) 2020-07-02
US20200268843A1 (en) 2020-08-27
WO2017009843A2 (en) 2017-01-19
MX2020004969A (es) 2020-08-20
JP2022113913A (ja) 2022-08-04
WO2017009842A2 (en) 2017-01-19
US11648293B2 (en) 2023-05-16
KR20180063881A (ko) 2018-06-12
CA2986705A1 (en) 2017-01-19
US10682390B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
US11590200B2 (en) Compositions and methods for treating cancer
HK40067545A (en) Compositions and methods for treating cancer
HK40039521A (en) Compositions and methods for treating cancer
HK40032310A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190603

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20191004

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201104